TrialNet TOPPLE Study for People with Type 1 Diabetes
- Study HIC#:2000029217
- Last Updated:12/22/2022
TrialNet is testing the safety of a new treatment, NNC0361-0041, in adults, 18-45, with Type 1 Diabetes (T1D) diagnosed within the past 48 months. The treatment is a plasmid vector designed to transfer DNA into cells, where it can communicate with the immune system. Earlier studies in the lab show this treatment might retrain the immune system to stop its attack on insulin-producing beta cells.
While plasmids are small circular pieces of DNA, they do not change your DNA. They are currently being studied in many clinical trials for other conditions.
This study has a 12-week treatment phase, followed by 9 months of follow up.
- Age18 years - 45 years
- Start Date11/17/2020
- End Date12/26/2021
Main Eligibility Requirements
- Age 18-45
- T1D diagnosis in past 48 months.